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Abstract. The emergence of chloroquine resistance, and a world-wide scarcity of quinine, have resulted in a
search for newer antimalarial drugs directed against falciparum malaria. Allopurinol causes virtually complete inhibition of purine biosynthesis of malaria parasites, which may prove lethal to the parasites. This study was designed
to examine if allopurinol is additive to quinine in the treatment of acute falciparum malaria. Forty-seven Asian-Indian
adults with acute complicated falciparum malaria were assigned to a treatment period of five days. They were
randomly assigned to receive either oral allopurinol (12 mg/kg in three divided doses for five days) plus quinine (600
mg intravenously every 8 hr for two days, followed by 600 mg orally every 8 hr for three days ) (n 5 24), or quinine
alone (600 mg intravenously every 8 hr for two days, followed by 600 mg orally every 8 hr for three days) (n 5
23). The responses were assessed by parasite clearance time, defervescence time, splenomegaly disappearance time,
and cure rate. In the allopurinol-quinine (ALLQUIN)–treated group, all the durations were significantly shorter than
those in the quinine alone (QUIN)–treated group. They were ALLQUIN versus QUIN (mean 6 SD 5 65.33 6 11.47
hr versus 76.78 6 18.20 hr; P 5 0.0214; 57.66 6 13.01 hr versus 82.52 6 23.55 hr, P 5 0.0002; 10 6 1.64 days
versus 14.65 6 2.4 days; P 5 0.0002), respectively. The cure rate was higher in the ALLQUIN group (91.7%) than
in the QUIN group (87%). However, this difference was not statistically significant. Therefore, this study indicates
that allopurinol can be an additive to quinine to bring about both faster eradication of Plasmodium falciparum and
clinical remission than with quinine alone.
With the emergence of Plasmodium falciparum strains resistant to chloroquine and/or to sulfadoxine/pyrimethamine
in almost all endemic areas,1 quinine has remained one of
the few drugs for treatment of falciparum malaria2 and has
caused a resurgence of its use.3 Quinine administered daily
for three days clears parasitemia within a few days; but after
two to four weeks, parasitemia recrudesces.4 Although, during successful antimalarial treatment, parasite clearance time
in African children with severe P. falciparum infection did
not usually exceed 60 hr, some parasites remained alive despite exposure to extremely high concentrations of quinine
for up to 96 hr.2
Allopurinol has a broad antiprotozoal activity.5 Due to a
lack of a de novo purine biosynthesis pathway,6 and malaria
parasite’s nonspecific hypoxanthine guanine phosphoribosyl
transferase, malaria parasites use allopurinol as a hypoxanthine analog.7 Consequently, 4-aminopyrazolopyrimidine ribonucleotide triphosphate, a highly toxic analog of adenosine triphosphate is formed and incorporated into protozoal
ribonucleic acid.8 Allopurinol thus brings about virtually
complete cessation of intraerythrocytic (IE) plasmodial purine biosynthesis and protein metabolism, which prove lethal
to the parasites. Allopurinol (11–36 mg/kg/day) is rapidly
absorbed after ingestion, and has a half-life of 2–3 hr (its
primary active metabolite oxypurinol has a half-life of 18–
30 hr). This drug is usually given daily in three divided
doses.8, 9
This study was designed to compare the effectiveness of
a combined regimen of allopurinol plus quinine (ALLQUIN)
with that of standard regimen of quinine (QUIN) in the treatment of acute complicated falciparum malaria. The objectives were to determine whether ALLQUIN therapy would
shorten the overall course of the infection and produce a
higher cure rate in falciparum malaria.

PATIENTS, MATERIALS, AND METHODS

Adult patients with acute, complicated, falciparum malaria
admitted to Jawaharal Nehru Hospital and Research Center
(Bhilainagar, India) during a two-year period (1993–1994)
were included in this study. The diagnosis was confirmed in
all patients by finding asexual forms of P. falciparum in the
peripheral blood. Written informed consent for investigation,
treatment, and follow-up were obtained from all patients or
their family members. The study was reviewed and approved
by Hospital Ethical Committee. Patients who had a known
or suspected history of allergy to allopurinol or quinine, a
history of recent antimalarial drug treatment, and female patients who were pregnant or nursing babies were excluded
from the study. Parasite identification was done on thin and
thick Leishman-stained peripheral blood smears.
On thick blood smears, parasites per 200 white blood cells
(WBCs) were counted and converted to parasites/ml by using
the WBC count. On thin blood smears, parasites for 1,000
red blood cells were counted and converted to percent of
parasitized erythrocytes. Parasites were counted in this manner every 8 hr for 72 hr, then every 12 hr until none could
be detected, and finally, once a week for eight weeks. The
body temperature was recorded every 4 hr until the patient
was afebrile for 24 hr, then once a day until discharge, and
once a week thereafter for eight weeks (56 days).
The eight weeks follow-up for patients given ALLQUIN
was necessary because of the long half-life of its active metabolite oxypurinol, and recrudescences of malaria that occur
after 35 days of treatment with nonquinine drugs.1 With antimalarial drugs that have shorter half life, such as quinine,
most recrudescences occur within four weeks of treatment.
Patients with severe complicated falciparum malaria were
diagnosed according to the World Health Organization (Geneva, Switzerland).10 Thus, severe complicated malaria was
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TABLE 1
Admission clinical and laboratory data of patients with complicated falciparum malaria*
Allopurinol† plus quinine‡

No. of patients
Males
Females
Age (years)
Weight (kg)
Temperature (8C)
Parasitemia (%)
Hemoglobin (g/dl)
Unconjugated bilirubin (mg/dl)
ALT (U/liter)
Serum creatinine (mg/dl)
Blood urea nitrogen (mg/dl)

24
14
10
32.3
53.6
38.3
6.4
8.4
1.9
110
4.3
32

(13–66)
(32–86)
(37.5–41.8)
(5.2–10)
(5.6–14.2)
(1.4–2.5)
(80–140)
(3.4–4)
(26–40)

Quinine‡

23
15
8
34.04
52.3
38.4
5.6
8.5
2
113
4.7
50

(15–56)
(37–85)
(37.6–41.6)
(5.4–20)
(6.2–14)
(1.8–2.2)
(105–120)
(3.2–8)
(26–40)

* Values in parentheses are ranges. ALT 5 alanine aminotransferase.
† See Materials and Methods for dosage details.
‡ See Materials and Methods for dosage details given alone/along with allopurinol.

diagnosed in our study if patients had more than 5% parasitized erythrocytes with or without hyperpyrexia (temperature $ 408C), and who were diagnosed to have cerebral malaria (after exclusion of other causes of encephalopathy by
clinical examination and laboratory investigations), and had
in addition jaundice (total bilirubin . 2 mg/dL) or oliguric
acute renal failure.
All hematologic, hepatic, and renal functions tests were
done upon admission to hospital and during follow-up examinations. An electrocardiogram was recorded before initiation of treatment, and during and after the completion of
treatment. Evaluation of spleen size was done by palpation
before, during and after the completion of treatment. Patients
were randomly assigned (open randomization) into two treatment groups: 1) ALLQUIN: allopurinol (12 mg/kg in three
equally divided doses orally or through a nasogastric tube
daily for five days) plus quinine (600 mg intravenously every 8 hr for two days followed by 600 mg orally every 8 hr
for three days; and 2) QUIN: quinine (600 mg intravenously
every 8 hr for two days followed by 600 mg orally every 8
hr for three days). Patients were kept in the hospital for a
minimum period of seven days. The parameters used in outcome determinations included 1) defervescence time, 2) parasite clearance time, 3) spleen size, and 4) cure rate. After
discharge from the hospital, patients were followed up at
weekly intervals for eight weeks. They were considered to
be cured if there was no recrudescence of malaria within 28
days after the last treatment for QUIN group and 56 days
for ALLQUIN group.
Statistical analysis. To compare the outcome variables,
mean parasite clearance time, mean defervescence time, and
mean splenomegaly disappearance time between the two
study groups (QUIN and ALLQUIN), a multivariate analysis
of covariance was conducted. In this analysis, the effect of
the treatment is adjusted for the effects of the covariates,
age, weight, and sex. A chi-square analysis was done to
compare the cure rate between the two study groups.
RESULTS

The clinical data are presented in Table 1. Twenty-four
patients (14 males and 10 females) were treated with the
ALLQUIN combination. All patients completed the treat-

ment. The mean age was 32.3 years (range 5 13–66 years)
and the mean parasitemia was 6.4% (5.2–10%) (range 5
0.011–10%). All patients had fever at the time of admission
with a mean 6 SD temperature of 38.3 6 1.058C). Twentythree patients (15 males and 8 females) were treated with
QUIN alone. All patients completed the treatment. The mean
age in the QUIN group was 34.04 years (range 5 15–56
years) and the mean parasitemia was 5.6% (5.4–20%) (range
5 0.01–20%). All patients had fever at the time of admission
with a mean 6 SD temperature of 38.4 6 1.058C).
Patients in both treatment groups were anemic. The mean
serum bilirubin and transminase levels were mildly elevated.
These levels returned to normal within seven days. Many
patients had acute oliguric renal failure in each group at the
time of admission. Mean serum creatinine and blood urea
nitrogen levels were elevated in both groups. These levels
returned to normal in 10 days with conservative management. In three cases of cerebral malaria, consciousness was
regained within 48 hr of initiation of therapy without neurologic sequelae. Two patients had severe falciparum malaria
with uneventful recovery and were discharged on the tenth
hospital day.
The treatment responses in both groups are presented in
Table 2. The multivariate analysis of covariance resulted in
a P value 5 0.0001 for the group effect, indicating that the
means for defervescence time, parasite clearance time, and
splenomegaly disappearance time differ significantly between the two groups after adjusting for the effects of age,
weight, and sex. The P values for each individual outcome
variable are given in Table 2. In the ALLQUIN group, there
was rapid remission of fever in all patients. The mean 6 SD
defervescence time was 57.6 6 13.01 hr (range 5 30–96
hr). The mean 6 SD parasite clearance time in this group
was 65.33 6 11.48 hr (range 5 48–96 hr). The mean 6 SD
splenomegaly disappearance time was 10 6 1.64 days (range
5 7–13 days). In the QUIN group there was slow remission
of fever. The mean 6 SD defervescence time was 82.52 6
23.55 hr (range 5 48–144 hr). The mean 6 SD parasite
clearance time was 76.78 6 8.21 days (range 5 48–120
days). Disappearance of splenomegaly was observed in
56.5% of patients by 14 days and 100% of patients by 18
days. Mean 6 SD splenomegaly disappearance time was
14.65 6 2.40 days (range 5 8–18 days). Thus, mean defer-
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TABLE 2
Comparison of treatment responses between two groups in patients with falciparum malaria*

Mean defervescence time (hr)
Mean parasite clearance time (hr)
Splenomegaly disappearance time (days)
Cure rate at 28 days (%)

Allopurinol plus quinine
(n 5 24)

Quinine
(n 5 23)

P

57.67 6 13.01
65.33 6 11.48
10 6 1.64
91.7

82.52 6 23.55
76.78 6 18.21
14.65 6 2.4
87

0.0002
0.0214
0.0002
0.666

* n 5 number of patients. Values are the mean 6 SD.

vescence time, parasite clearance time and splenomegaly
disappearance were significantly longer in the QUIN group
than in the ALLQUIN group (Table 2).
The overall cure rate for ALLQUIN group was 91.7% at
the end of both 28 and 56 days. The overall cure rate for
QUIN group was 87% at the end of 28 days (Table 2). The
difference in cure rate between the two groups was not significant (P 5 0.666, by chi-square test).
Adverse reactions in both treatment groups are presented
in Table 3. The incidence and severity of adverse reactions
were not significantly different between the two treatment
groups.
DISCUSSION

Over the past 30 years there has been a gradual realization
that malaria cannot be completely eradicated and most of the
studies have emphasized the need for reliance on antimalarial drugs.11 The emergence of P. falciparum resistant to existing antimalarial drugs has warranted a search for new therapeutic endeavors for falciparum malaria. A rational approach to the selection of new drugs requires a detailed
knowledge of enzymology and metabolism of both the parasite and the host and to find the differences that can be
exploited for selective destruction of the parasites.6 In view
of the prohibitive cost of developing and licensing new antimalarial formulations,3 the demonstration of useful antimalarial activity in a drug already licensed for another purpose will be an important advance. Both in vitro and in vivo
studies have shown that certain inosine analogs have broad
antiprotozoal activity.5 One such inosine analog is allopurinol, which has been shown to bring about virtually complete
cessation of IE plasmodial purine biosynthesis and protein
metabolism in in vitro studies and models.6, 7, 12 The selective

TABLE 3
Adverse reactions

Cinchonism
Nausea
Abdominal pain
Vomiting
Diarrhea
Loss of appetite
Myalgia
Bradycardia
Depressed white blood cell count
Skin rashes
Eosinophilia

Allopurinol
plus quinine
(n 5 24)

Quinine
(n 5 23)

2
2
1
1
4
4
2
0
1
3
3

4
3
3
3
3
6
0
2
0
0
0

antiparasitic action of allopurinol is believed to be due to its
incorporation into the protozoal but not the mammalian purine salvage pathway.8 However, the lack of in vivo effect,
and the report on the enhancement of parasite multiplication
in rodent malaria by P. berghei can be explained by the fact
that smaller animals may metabolize the drug more quickly,
and in a different way and with subgenera of Plasmodium
that less closely resemble those affecting humans.13, 14
The disappointing results of clinical trial by Phillips and
others14 strengthen the evidence that laboratory-derived,
highly chloroquine-resistant strains of P. berghei in mice are
not always an adequate model for P. falciparum in humans,13
and that the human malarias are different from the rodent
malaria.
Work on the response of P. falciparum in vitro to various
4-aminoquinolines has led other workers to doubt the relevance of chloroquine-uptake studies in P. berghei to the
mechanism of resistance in P. berghei to the mechanism of
resistance in P. falciparum.15 However, a distinct possibility
remains that allopurinol would block the metabolism of quinine leading to higher effective in vivo dosage of quinine.
In this way, these two drugs may appear additive.
Vivax malaria occurred during follow-up of patients with
falciparum malaria in whom initially mixed malarial infection was missed or not identified as a result of treatment
with pyrimethamine-sulfadoxine, qinghaosu derivatives, and
mefloquine.1, 16, 17 With ALLQUIN treatment, none of the patients had P. vivax in peripheral blood during follow-up. It
has been reported that P. vivax infection is not detectable
until P. falciparum has been eradicated by treatment with
quinine,1, 16, 17 suggesting that a mixed infection may occur.
Allopurinol has a parasiticidal effect on P. vivax. We have
observed a curative effect of allopurinol when combined
with quinine (ALLQUIN) in the treatment of mixed malarial
infections caused by P. falciparum and P. vivax (Sarma
PSA, Mandal AK, unpublished data).
Use of quinine for seven days resulted in higher recrudescence rate and higher incidence of cinchonism.1 Quinine
used for 14 days to prevent delayed recrudescences still results in 33.3% recrudescence.18 The established second-line
drug regimen for treatment of severe complicated falciparum
malaria (excluding pregnant women and children) is quinine
plus tetracycline for seven days.1 The cure rate for quinine/
tetracycline is 93%, but the long-term treatment decreases
compliance.1, 4
We have investigated the effectiveness and safety of allopurinol in acute severe and complicated falciparum malaria. The combination therapy is well tolerated and reduces
parasitemia more rapidly than by quinine alone. The defervescence time is significantly shorter and the adverse effects

ALLOPURINOL FOR ACUTE FALCIPARUM MALARIA

are rather mild. The splenomegaly disappearance time is
shorter than in patients treated with quinine alone. However,
the cure rate was comparable between the two groups.
In conclusion, this study suggests that allopurinol is an
additive to quinine, and that the combination therapy effectively cures acute, complicated, falciparum malaria. This
combination therapy is worthy of further trials in falciparum
malaria.
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